GBT Announces New Employment Inducement Grants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
RBC Capital Steps Aside on Global Blood Therapeutics (GBT), 'Oxbryta Beat Confirms Value; With Solid Outcome'
August 8, 2022 4:19 PM EDTRBC Capital analyst Gregory Renza downgraded Global Blood Therapeutics (NASDAQ: GBT) from Outperform to Sector Perform with a price target of $68.50 (from $60.00).
The analyst comments "Srong Oxbryta revenue beat for 2Q22 and the PFE acquisition underscore the strong fundamentals... More
